News | 18 January 2024
NATCO invests US$ 2 million in Cellogen Therapeutics
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Agreed Price of US$43 per share to deliver 48% premium to unaffected price on May 25, 2023
The bold, dynamic, and new logo unveiled in this process captures the essence of the 'Better Together' theme
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio
Automated parallel capillary electrophoresis system simplifies protein analysis
Collaboration streamlines patient access to oncology clinical trials
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Trastuzumab biosimilar is a humanized monoclonal antibody for treating metastatic breast cancer
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
The three-day event in Bengaluru was conducted in collaboration with the Karnataka Ophthalmology Society (KOS) and the Bangalore Ophthalmology Society (BOS)
Approval based on a separate phase III trial among Chinese patients reinforcing mepolizumab’s efficacy and safety data
The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars
Shivalik Rasayan Limited have successfully submitted USMDF for API " Palbociclib " to USFDA
A 'better for you' organic brand spanning Food & Beverages and Nutraceutical categories
The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects
Varenicline Tablets (RLD Chantix) had estimated annual sales of US $412 million in the US
The three-day forum will feature global leaders, scientists, regulatory body representatives, industry associations, and academia among many others
Argo will receive upfront payments of US$ 185 million from Novartis and is eligible to receive potential option and milestone payments as well as tiered royalties on commercial sales.
Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb
Subscribe To Our Newsletter & Stay Updated
